Weight-loss injections are prescription medicines for obesity, not a shortcut for a few kilos. In December 2025, WHO issued its first guideline on these GLP-1 medicines, calling obesity a chronic, relapsing disease and conditionally recommending them for adults with obesity, excluding pregnant women, as part of care that also includes healthy diets, regular physical activity and support from health professionals. In WHO’s words, medication alone won’t solve the problem.
We are a fitness and nutrition coaching program, not doctors, and we don’t prescribe or recommend any medicine. This guide explains the facts so you can have a better conversation with your own doctor.
What they are and how they work
- Semaglutide is a GLP-1 medicine. The NHS lists it as Wegovy for obesity and Ozempic (injection) or Rybelsus (tablet) for type 2 diabetes. In India, Wegovy is also marketed as Poviztra and Ozempic as Extensior, and generic semaglutide has been available since March 2026.
- Tirzepatide (Mounjaro) acts on two gut hormones, GLP-1 and GIP.
- Both are weekly injections. The NHS says they work for weight loss by reducing your appetite and helping you feel fuller for longer, and that they are used together with diet and exercise changes.
What the trials show
| Trial | What happened |
|---|---|
| STEP 1: semaglutide 2.4 mg, 1,961 adults, 68 weeks | Average weight change −14.9%, compared with −2.4% on placebo, with lifestyle support in both groups |
| SURMOUNT-1: tirzepatide, 2,539 adults, 72 weeks | Average weight change −15.0% to −20.9% depending on the dose, compared with −3.1% on placebo |
| STEP 1 extension: one year after stopping | People regained about two-thirds of the weight they had lost, and most heart and blood sugar improvements went back towards where they started |
The trials included adults with a BMI of 30 or more, or 27 or more with a weight-related health problem, and none of them had diabetes. Averages hide a wide range: some people lose much more, some much less.
Side effects
The NHS lists these as common for semaglutide and tirzepatide:
- Feeling or being sick, and diarrhoea or constipation (and stomach pain with tirzepatide).
- Feeling tired.
- Itchy or red skin where you inject.
- Hair loss (see our hair fall guide).
Rare but serious side effects include an allergic reaction, an inflamed pancreas (severe stomach or back pain that doesn’t go away), low blood sugar if used with other diabetes medicines, and, with tirzepatide, gallstones. Get medical help urgently for these. The NHS also says the medicines may not be suitable if you have had pancreatitis, and that semaglutide can interact with levothyroxine, the thyroid medicine many Indian women take (see our thyroid guide).
What women need to know
- Pregnancy: the NHS says neither medicine is used in pregnancy. If you want to get pregnant, stop semaglutide at least 2 months, and tirzepatide at least 4 weeks, before trying, with your doctor’s advice.
- Breastfeeding: neither is used while breastfeeding, the NHS says.
- Contraception: use contraception if you could get pregnant while on semaglutide. With tirzepatide, the NHS advises an extra barrier method, such as condoms, for 4 weeks after starting and for 4 weeks after each dose increase.
- PCOS: if you have PCOS, talk to your doctor about your whole plan; our PCOS after 30 guide lists the checks that matter.
Buying safely in India
After Novo Nordisk’s semaglutide patent protection in India ended in March 2026, the first generic versions from Indian drugmakers launched within days. Lower prices make them easier to get, which is exactly why caution matters:
- Use them only with a prescription from a doctor who has checked your health and will follow you up.
- Buy from a licensed pharmacy, never from social media sellers. WHO warns that demand has fuelled falsified and substandard GLP-1 products, and the NHS warns that some websites sell fake weight-loss medicines.
- Never share pens, and don’t stop or change your dose on your own; the NHS says to talk to your doctor before stopping.
Why muscle and habits still matter
WHO’s second recommendation is that people prescribed these medicines may be offered structured programmes of healthy eating and physical activity. Practically:
- Protect your muscle. When you eat less, you lose some muscle along with fat. In a 2012 meta-analysis of weight-loss trials, higher-protein diets helped people keep more lean mass, and WHO recommends strength training on at least 2 days a week. See our strength training guide and protein guide for vegetarian women.
- Eat enough, and eat well. With a small appetite, every meal counts: dal, paneer, curd, eggs, sabzi and some grains. Our Indian diet guide shows the plate.
- Plan for the long term. The STEP 1 extension shows that weight tends to return when treatment and support stop, so the habits you build while on medicine are what you keep.
Not sure whether your weight counts as obesity for an Indian woman? Our BMI and waist guide explains the Asian cut-offs.
How FunDa helps
The Superwoman Club coaches the habits WHO puts alongside medicine: strength and dance workouts at home, protein-rich Indian meals with dietitian support, sleep and stress routines, and daily check-ins. We don’t prescribe, recommend or sell any medicine; if you use one, your doctor manages it, and we coach your habits alongside their care. Results vary from person to person.
Sources
- World Health Organization. WHO issues global guideline on the use of GLP-1 medicines in treating obesity (1 December 2025).
- NHS. Semaglutide (reviewed 15 May 2026).
- NHS. Tirzepatide (reviewed 15 May 2026).
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.
- CNBC. India is launching cheap weight-loss drugs, but Novo Nordisk is betting its brands will stay on top (23 March 2026).
- Wycherley TP et al. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012;96(6):1281-98.
- Bull FC et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020.
How we write our guides: read our editorial and evidence policy.